| Literature DB >> 31035452 |
Ramesh Subramani1, Detmer Sipkema2.
Abstract
Rare actinomycetes are prolific in the marine environment; however, knowledge about their diversity, distribution and biochemistry is limited. Marine rare actinomycetes represent a rather untapped source of chemically diverse secondary metabolites and novel bioactive compounds. In this review, we aim to summarize the present knowledge on the isolation, diversity, distribution and natural product discovery of marine rare actinomycetes reported from mid-2013 to 2017. A total of 97 new species, representing 9 novel genera and belonging to 27 families of marine rare actinomycetes have been reported, with the highest numbers of novel isolates from the families Pseudonocardiaceae, Demequinaceae, Micromonosporaceae and Nocardioidaceae. Additionally, this study reviewed 167 new bioactive compounds produced by 58 different rare actinomycete species representing 24 genera. Most of the compounds produced by the marine rare actinomycetes present antibacterial, antifungal, antiparasitic, anticancer or antimalarial activities. The highest numbers of natural products were derived from the genera Nocardiopsis, Micromonospora, Salinispora and Pseudonocardia. Members of the genus Micromonospora were revealed to be the richest source of chemically diverse and unique bioactive natural products.Entities:
Keywords: bioactive compounds; cultivation; marine actinobacteria; natural products; rare actinomycetes
Mesh:
Substances:
Year: 2019 PMID: 31035452 PMCID: PMC6562664 DOI: 10.3390/md17050249
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Pre-treatment methods for the selective isolation of marine rare actinomycetes.
| Pre-treatment | Marine Source | Isolation Medium | Incubation Temperature/Time | Target Rare Genera | Ref. |
|---|---|---|---|---|---|
|
| |||||
| Incubation in water bath at 50 °C for 60 min | WS | Starch-casein agar + 10 µg nalidixic acid, 25 µg nystatin and 10 µg cycloheximide | 24 °C for 28 days |
| [ |
| WS | M1 agar + 75 µg cycloheximide | 20–24 °C for 14–28 days |
| [ | |
| 50 °C for 15 min | WS | Starch-casein agar + 10 µg nystatin and 25 µg cycloheximide | 28 °C for 7 days | [ | |
| 55 °C for 20 min | WS | Glucose peptone tryptone agar + 50 mg nystatin, 50 mg cycloheximide, 25 mg novobiocin and 20 mg nalidixic acid | 28 °C for 21 days |
| [ |
| Incubation in water bath at 55 °C for 6 min | DS | M1–M5 agar + 100 µg cycloheximide and 5 µg rifampin | 25–28 °C for 2–6 weeks | [ | |
| Incubation in water bath at 60 °C for 10 min | DS | M1–M12 agar + 100 µg cycloheximide and 50 µg nystatin | 28 °C for 3 months | [ | |
| Speedvac 30 °C, 16 h; 120 °C, 60 min | DS | Different selective media + cycloheximide (50 μg/mL), nystatin (75 μg/mL) and nalidixic acid (30 μg/mL) | 20 °C for 2–6 weeks | Rare actinomycetes | [ |
| 41 °C for 10, 30 and 60 days | DS | Different selective media | 28 °C for 2–3 weeks | [ | |
| 70 °C for 15 min | WS | Different selective media | 25 °C for 4 weeks | [ | |
| 55 °C for 15 min | DS | Asparagine-glucose agar medium + nalidixic acid (25 μg/mL) and secnidazole (25 μg/mL) | 25 °C for 2 weeks |
| [ |
| 45, 55 or 65 °C for 30 min | WS | ISP-3 and ISP-4 + cycloheximide (50 μg/mL), nystatin (50 μg/mL), and nalidixic acid (20 μg/mL) | 27 °C for 3 weeks |
| [ |
| 60 °C for 6 min | WS | M1 medium and Glucose-yeast extract medium + nystatin (50 μg/mL), and nalidixic acid (10 μg/mL) | 25 °C for 6 weeks | [ | |
|
| |||||
| Dry in laminar air flow hood; Stamping | WS/DS | M1–M12 agar + 100 µg cycloheximide and 50 µg nystatin | 28 °C for 3 months | [ | |
|
| |||||
| Shake with glass beads for 30 s and settled for 5 min | WS | Different selective media + cycloheximide (50 μg/mL), nystatin (75 μg/mL) and nalidixic acid (30 μg/mL) | 20 °C for 6 weeks | Rare actinomycetes | [ |
|
| |||||
| 1.5% phenol + 30 min at 30 °C | DS | Different selective media + cycloheximide (50 μg/mL), nystatin (75 μg/mL) and nalidixic acid (30 μg/mL) | 20 °C for 2–6 weeks |
| [ |
| 0.02% benzethonium chloride + 30 min at 30 °C | DS | Different selective media + cycloheximide (50 μg/mL), nystatin (75 μg/mL) and nalidixic acid (30 μg/mL) | 20 °C for 2–6 weeks | Rare actinomycetes | [ |
| 0.05% SDS and 6% yeast extract (40 °C, 200 rpm, 30 min) | DS | Different selective media + cycloheximide (25–100 μg/mL) and nystatin (25–50 μg/mL) | 28 °C for 1–12 weeks | [ | |
| 1.5% phenol | DS | Different selective media + cycloheximide (50 μg/mL), nystatin (75 μg/mL) and nalidixic acid (30 μg/mL) | 20 °C for 2–6 weeks | Rare actinomycetes | [ |
| Chloramine-T | DS | Different selective media + cycloheximide (25–100 μg/mL) and nystatin (25–50 μg/mL) | 28 °C for 1–12 weeks | [ | |
|
| |||||
| Differential centrifugation | WS | Selective media | 28 °C for 12 weeks | [ | |
|
| |||||
| Freeze (−20 °C, 24 h), thawed, dilution | WS | M1-M12 agar + 100 µg cycloheximide and 50 µg nystatin | 28 °C for 3 months | [ | |
| Freeze at −18 °C | WS | Different selective media + nystatin (50 μg/mL) and nalidixic acid (10 μg/mL) | 28 °C for 2–3 weeks | [ | |
|
| |||||
| UV irradiation for 30 s (distance 20 cm, 254 nm, 15 W) | WS | Different selective media + nystatin (50 μg/mL) and nalidixic acid (10 μg/mL) | 28 °C for 2–3 weeks | [ | |
| Superhigh frequency radiation inmicrowave oven for 45 s (2460 MHz, 80 W) | WS | Different selective media + nystatin (50 μg/mL) and nalidixic acid (10 μg/mL) | 28 °C for 2–3 weeks | [ | |
| Extremely high frequency radiation (1 kHz within wavelength band of 8–11.5 mm) | WS | Different selective media + nystatin (50 μg/mL) and nalidixic acid (10 μg/mL) | 28 °C for 2–3 weeks | [ | |
WS: Wet Sediment; DS: Dried Sediment.
New species of rare actinomycetes from marine sediments reported during the period of mid 2013–2017.
| Strain/Family | Nature of Sample | Isolation Medium | Ref. |
|---|---|---|---|
| Deep marine sediment at a depth of 60 m | SM3 medium (yeast nitrogen base 67.0 g, casamino acids 100 mg were added to a litre of distilled water and the solution sterilised using cellulose filters (0.20 mm) prior to the addition of sterilised di-potassium hydrogen phosphate (200 mL; 10%, w/v); 100 mL of this basal medium was added to 900 mL of sterilised molten agar (1.5%, w/v) followed by filter sterilised solutions of D(+) melezitose (1%, w/v), cycloheximide (50 µg mL−1), neomycin sulphate (4 µg mL−1) and nystatin (50 µg mL−1) | [ | |
| Marine sediment | Trypticase soy broth agar (DSMZ Medium 535) | [ | |
| Marine sediment at a depth of 2439 m | Starch casein nitrate agar medium (10.0 g soluble starch, 0.3 g casein, 2 g KNO3, 0.05 g MgSO4.7H2O, 35 g NaCl, 2 g K2HPO4, 0.02 g CaCO3, 10 mg FeSO4, 20 g agar, distilled water 1 L) | [ | |
| Sea sediment at a depth of 652 m | DSMZ 621 medium (250 mg each of Bacto peptone (Difco), Bacto yeast extract and glucose, as well as 20 mL Hutner’s basal salts medium, 10 mL vitamin solution no. 6, 35 g NaCl and 1000 mL distilled water) | [ | |
| Marine sediment | CMKA medium [(L−1) 0.5 g casein hydrolysate, 1.5 g mannitol, 1 g KNO3, 2 g (NH4)2SO4, 0.5 g K2HPO4, 0.5 g CaCO3, 20 g agar]. The multi-salts comprised of 49% (w/w) MgCl2.6H2O, 32% (w/w) NaCl, 14 % (w/w) CaCl2 and 5 % (w/w) KCl | [ | |
| Marine sediment | CMKA medium [(L−1) 0.5 g casein hydrolysate, 1.5 g mannitol, 1 g KNO3, 2 g (NH4)2SO4, 0.5 g K2HPO4, 0.5 g CaCO3, 20 g agar]. The multi-salts comprised of 49% (w/w) MgCl2.6H2O, 32% (w/w) NaCl, 14 % (w/w) CaCl2 and 5 % (w/w) KCl | [ | |
| Deep-sea sediment at a depth of −2945 m | Modified Zobell 2216E agar (1.0 g yeast extract, 5.0 g tryptone, 34 g NaCl, 15 g agar and 1 L distilled water) | [ | |
| Marine sediment at a depth of −7118 m | Modified ZoBell 2216E agar plates (0.5% tryptone, 0.1% yeast extract, 3.4% sodium chloride and 1.8% agar) | [ | |
| Deep sub-seafloor sediment at a depth of 107.3–107.4 m | Marine agar 2216 (Difco) | [ | |
| Sea sediment at a depth of 880 m | DSMZ 621 medium (250 mg each of Bacto peptone (Difco), Bacto yeast extract and glucose, as well as 20 mL Hutner’s basal salts medium, 10 mL vitamin solution no. 6, 35 g NaCl and 1000 mL distilled water) | [ | |
| Marine sediment | Marine agar 2216 (Becton Dickinson) | [ | |
| Marine beach sediment | Starch casein agar (1% soluble starch, 0.03% casein, 0.2% KNO3, 0.2% NaCl, 0.005% MgSO4.7H2O, 0.2% K2HPO4, 0.02% CaCO3, 0.001% FeSO4.7H2O, 1.8% agar) | [ | |
| Marine sediment at a depth of −7068 m | Seawater agar (15.0 g agar and 1 L natural seawater) | [ | |
| Marine sediment | Agar medium (glycerine 10.0 g, | [ | |
| Marine sediment at a depth of 2918 m | Agar medium (glycerine 10.0 g, | [ | |
| Marine sediment at a depth of 2460 m | Gauze’s synthetic medium no. 1 (soluble starch 20.0 g, KNO3 1.0 g, NaCl 0.5 g, MgSO4.7H2O, 0.5 g, K2HPO4 0.5 g, FeSO4.7H2O 10.0 mg, agar 15.0 g and distilled water 1.0 L) | [ | |
| Hydrothermal sediment at a depth of 2943 m | Modified ZoBell 2216E agar plates (0.5% tryptone, 0.1% yeast extract, 3.4% sodium chloride and 1.8% agar) | [ | |
| Sea sediment | NBRC medium 802 [Polypepton (Wako) 2 g, yeast extract 0.4 g, MgSO4.7H2O 0.2 g and agar 15 g in 1.0 L distilled water supplemented with NaCl (30 g−l), cycloheximide (50 mg−l) and nalidixic acid (20 mg−l)]. | [ | |
| Marine sediment | Marine agar (HiMedia) | [ | |
| Sea sediment at a depth of 2093 m | Yeast extract/malt extract agar (1 L seawater, 0.5 g malt extract, 0.2 g yeast extract, 0.1 g glucose and 20 g agar) | [ | |
| Sea sediment | NBRC medium 802 (0.2% polypeptone, 0.04% yeast extract, 0.02% MgSO4.7H2O and 1.5% agar) | [ | |
| Marine sediment | Marine agar 2216 (Difco) | [ | |
| Deep-sea sediment at a depth of 7118 m | Modified ISP 1 (1 L natural seawater, 10 g glucose, 5 g peptone, 5 g yeast extract, 0.2 g MgSO4.7H2O, 10 g NaHCO3, 27 g Na2CO3.10H2O and 15 g agar) | [ | |
| Marine sediment | No. 38 medium [(L−1) yeast extract 0.4 g; glucose 0.4 g; malt extract 0.4 g; B-vitamin trace 1 mL (0.5 mg each of thiamine-HCl (B1), riboflavin, niacin, pyridoxin, ca-pantothenate, inositol, | [ | |
| Deep subseafloor sediment | Marine agar 2216 (Difco) | [ | |
| Deep-sea sediment at a depth of 2439 m | HP agar medium (5 g fucose, 1 g proline, 1 g (NH4)2SO4, 2 g CaCl2, 1 g K2HPO4, B vitamin mixture (0.5 mg each thiamine hydrochloride, riboflavin, niacin, pyridoxine, calcium pantothenate, inositol and | [ | |
| Deep subsurface sediment at a depth of 297 m | Anoxic F4 medium (0.4 g NaCl, 0.4 g NH4Cl, 0.3 g MgCl2.6H2O, 0.05 g CaCl2.2H2O, 1 g yeast extract, 2 g peptone, 1 g glucose, 1 g succinic anhydride, 7.5 g NaHCO3, 0.5 g KH2PO4, 0.5 g Na2S, 1 mg resazurin and 1 L distilled water) | [ | |
| Sea sediment | Marine agar 2216 (Difco) | [ | |
| Marine sediment | Marine agar 2216 (Difco) | [ | |
| Coastal sediment | Starch arginine agar (2.5 g soluble starch, 1.0 g arginine, 1.0 g (NH4)2SO4, 2.0 g CaCl2, 1.0 g K2HPO4, 0.2 g MgSO4.7H2O, 10 mg FeSO4.7H2O, 15.0 g agar supplemented with 3% (w/v) NaCl, nystatin and nalidixic acid) | [ | |
| Marine sediment | M1 medium (10 g soluble starch, 4 g yeast extract, 2 g peptone, 18 g agar, and 1 L of natural seawater) | [ | |
| Marine sediment at a depth of 45 m | SM3 medium (Gauze’s medium 2) [20 g casaminoacids, 20 g soluble starch, 4 g yeast extract, 15 g agar, 1 L distilled water] supplemented with filter sterilised cycloheximide (50 µg mL−1), nalidixic acid (10 µg mL−1), novobiocin (10 µg mL−1) and nystatin (50 µg mL−1) | [ | |
| Marine sediment at a depth of 45 m | ISP 2 medium (yeast extract 4.0 g, malt extract 10.0 g, dextrose 4.0 g, distilled water 1 L and Bacto agar 20.0 g) | [ | |
| Tidal flat sediment | Marine agar 2216 (Becton Dickinson) | [ | |
| Tidal flat sediment | Marine agar 2216 (Difco) | [ | |
| Sea sediment | NBRC medium 802 (1.0% polypeptone, 0.2% yeast extract, 0.1% MgSO4.7H2O and 1.5% agar) | [ | |
| Hydrothermal sediment | ZoBell 2216E agar (0.5% tryptone, 0.1% yeast extract, 3.4%sodium chloride and 1.8% agar) | [ | |
| Marine Sediment at a depth of 141 m | Marine agar 2216 (Becton Dickinson) | [ | |
| Deep sea sediment at a depth of 6310 m water depth | Modified ZoBell 2216E agar (1.0 g yeast extract, 5.0 g tryptone, 1 L of clarified seawater, 15.0 g agar) | [ | |
| Seashore sediment | Medium R (NaCl 25 g, MgSO4.7H2O 9 g, CaCl2.2H2O 0.14 g, KCl 0.7 g, Na2.HPO4.12H2O 0.25 g, Na2-EDTA 30 mg, H2BO3 34 mg, FeSO4.7H2O 10 mg, FeCl3.6H2O 1.452 mg, MnCl2.4H2O 4.32 mg, ZnCl2 0.312 mg, CoCl2.6H2O 0.12 mg, NaBr 6.4 mg, Na2MoO.2H2O 0.63 mg, SrCl2.6H2O 3.04 mg, RbCl 0.1415 mg, LiCl 0.61 mg, KI 0.00655 mg, V2O5 0.001785 mg, Cycloheximide 50 mg, Griseofulvin 25 mg, Nalidixic acid 20 mg, Aztreonam 40 mg, RPMI1640 500 mg, Eagle Medium 500 mg, | [ | |
| Seashore sand | |||
| Marine sediment at a depth of −5233 m | Isolation medium (10 g glucose, 5 g peptone, 5 g yeast extract, 0.2 g MgSO4.7H2O, 10 g NaHCO3, 27 g Na2CO3.10H2O, 20 g agar and 1 L natural seawater) | [ | |
| Deep-sea sediment at a depth of −2461 m | ISP 2 medium (yeast extract 4.0 g, malt extract 10.0 g, dextrose 4.0 g, distilled water 1 L and Bacto agar 20.0 g) | [ | |
| Sea sediment | CMKA medium [(0.5 g casein acids hydrolysate, 1.5 g mannitol, 1 g KNO3, 2 g (NH4)2SO4, 0.5 g K2HPO4, 0.5 g CaCO3, 20 g agar and 20% (w/v) multi-salts]. The multi-salts comprised 49% (w/w) MgCl2, 32% (w/w) NaCl, 14% (w/w) CaCl2 and 5% (w/w) KCl | [ | |
| Marine sediment | CMKA medium [(0.5 g casein acids hydrolysate, 1.5 g mannitol, 1 g KNO3, 2 g (NH4)2SO4, 0.5 g K2HPO4, 0.5 g CaCO3, 20 g agar and 20% (w/v) multi-salts]. The multi-salts comprised 49% (w/w) MgCl2, 32% (w/w) NaCl, 14% (w/w) CaCl2 and 5% (w/w) KCl | [ | |
| Coastal sediment | Marine agar 2216 (Difco) | [ | |
| Sea sediment | NBRC medium 802 (1.0% polypeptone, 0.2% yeast extract, 0.1% MgSO4.7H2O and 1.5% agar) | [ |
New species of rare actinomycetes from seawater reported during the period of mid 2013–2017.
| Strain/Family | Nature of Sample | Isolation Medium | Ref. |
|---|---|---|---|
| Coastal seawater | Marine agar (Difco) | [ | |
| Seawater at a depth of 1 m | R2A agar (Difco) | [ | |
| Seawater at a depth of −7001 m | Modified ZoBell 2216E agar (1.0 g yeast extract, 5.0 g tryptone, 1 L clarificated seawater and 15.0 g agar) | [ | |
| Deep-seawater at a depth of 2800 m | ISP 2 medium (yeast extract 4.0 g, malt extract 10.0 g, dextrose 4.0 g, distilled water 1 L and Bacto agar 20.0 g) | [ | |
| Deep-sea hydrothermal plume water at a depth of 2800 m | ISP 2 medium (yeast extract 4.0 g, malt extract 10.0 g, dextrose 4.0 g, distilled water 1 L and Bacto agar 20.0 g) and SMPS (0.1 g peptone, 0.5 g mannitol, 3 g sea salt, 1000 mL distilled water, pH 7.5) agar, supplemented with nalidixic acid, cycloheximide and nystatin (each at 25 μg mL−1). | [ | |
| Seawater | Marine agar (Difco) | [ | |
| Seawater | SC-SW agar (1% soluble starch, 0.03% casein, 0.2% KNO3, 0.2% NaCl, 0.2% KH2PO4, 0.002% CaCO3, 0.005% MgSO4.7H2O, 0.001% FeSO4.7H2O, 1.8% agar, 60% natural seawater and 40% distilled water) | [ | |
| Seawater | Tryptic soy agar medium (HiMedia) | [ |
New species of symbiotic rare actinomycetes from eukaryotic hosts reported during the period of mid 2013–2017.
| Strain/Family | Nature of Sample | Isolation Medium | Reference |
|---|---|---|---|
| Marine sponge | Starch-casein nitrate seawater agar (10 g soluble starch, 1 g sodium caseinate, 0.5 g KH2PO4, 0.5 g MgSO4 and 18 g agar in 1 L of seawater) | [ | |
| Marine sponge at a depth of 5 m | Starch-casein nitrate agar (10 g soluble starch, 1 g sodium caseinate, 2 g KNO3, 0.5 g KH2PO4, 0.5 g MgSO4 and 18 g agar in 1 L seawater) | [ | |
| Marine coral | Isolation medium (yeast extract 0.25 g, K2HPO4 0.5 g, agar 12 g, 500 mL seawater and 500 mL distilled water) | [ | |
| Marine sponge | M1 medium [1% starch, 0.4% yeast extract, 0.2% peptone, 2% agar containing artificial seawater (33 g red sea salt L−1) amended with cycloheximide and nystatin (each at 25 µg mL−1)] | [ | |
| Moon jellyfish | Zobell marine agar (HiMedia) and Tryptic soy agar (HiMedia) | [ | |
| Marine teleost fish | Middlebrook 7H11 agar with oleic albumin dextrose catalase (OADC) enrichment (Becton Dickinson) | [ | |
| marine sponge | M1 agar (soluble starch 10 g L−1, yeast extract 4 g L−1, peptone 2 g L−1, agar 15 g L−1, 80% artificial seawater) | [ | |
| Purple sea urchin | Marine agar 2216 (Difco) | [ | |
| Marine green alga | Modified R2A medium (yeast extract 0.5 g, peptone 0.5 g, casein enzyme hydrolysate 0.5 g, yeast extract 0.5 g, glucose 0.5 g, water soluble starch 0.5 g, dipotassium phosphate 0.3 g, magnesium sulphate 0.05 g, sodium pyruvate 0.3 g, sodium chloride 20.0 g and distilled water 1000 mL) | [ | |
| Marine sponge | Modified starch-casein nitrate seawater agar containing 10 g soluble starch, 1 g sodium caseinate, 0.5 g KH2PO4, 0.5 g MgSO4 and 18 g agar in 1 L seawater, pH 8.3, supplemented with 50 mg nalidixic acid L−1 and 200 mg nystatin L−1 | [ | |
| Marine sponge | Tryptone soy agar (Oxoid) | [ | |
| Marine sponge | ISP 2 medium (yeast extract 4.0 g, malt extract 10.0 g, dextrose 4.0 g, distilled water 1 L and Bacto agar 20.0 g) | [ | |
| Marine sponge | Tryptic Soy Agar [Oxoid; prepared with 80% (v/v) artificial seawater] | [ | |
| Marine coral at a depth of 1500 m | 1/3 Tryptic soy agar (Merck) and and 1/6 M-BLEB agar (9 g MOPS BLEB base (Oxoid) in 1 L Cantabrian seawater, containing the antifungal cycloheximide (80 µg mL−1) and anti-Gram-negative bacteria nalidixic acid (20 mg mL−1) | [ |
New species of rare actinomycetes from mangrove environment reported during the period of mid 2013–2017.
| Strain/Family | Nature of Sample | Isolation Medium | Ref. |
|---|---|---|---|
| Sediment of mangrove tidal flat | 1/5 NBRC medium 802 [0.2% (w/v) polypeptone, 0.04% (w/v) yeast extract, 0.02% (w/v) MgSO4.7H2O and 1.5% (w/v) agar; pH 7.0] supplemented with 5.0% (w/v) NaCl, 0.005% (w/v) cycloheximide and 0.002% (w/v) nalidixic acid | [ | |
| Rhizosphere soil of mangrove | |||
| Soil of mangrove forest | |||
| Mud of mangrove tidal flat | |||
| Rhizosphere soil of mangrove | |||
| Soil of mangrove forest | |||
| Rhizosphere soil of mangrove | |||
| Mangrove soil | Glucose-peptone-tryptone agar supplemented with 50 mg nystatin L−1, 50 mg cycloheximide L−1, 25 mg novobiocin L−1 and 20 mg nalidixic acid L−1 | [ | |
| Mangrove soil | 1/10 ATCC 172 agar supplemented with nalidixic acid (10 µg mL−1), novobiocin (10 µg mL−1), nystatin (50 µg mL−1) and K2Cr2O7 (20 µg mL−1) | [ | |
| Mangrove soil | ATCC 172 agar | [ | |
| Mangrove sediment | AV medium (1.0 g glucose, 1.0 g glycerol, 0.3 g L-arginine, 0.3 g K2HPO4, 0.2 g MgSO4.7H2O, 0.3 g NaCl, 18 g agar, artificial seawater added up to 1 L) | [ | |
| Mangrove soil | Glucose-peptone-tryptone agar (glucose 10 g, peptone 5 g, tryptone 3 g, NaCl 5 g, agar 15 g, ddH2O 1 L supplemented with 50 mg/L of nystatin, 50 mg/L of cycloheximide, 25 mg/L of novobiocin and 20 mg/L of nalidixic acid) | [ | |
| Mangrove sediment | Humic acid vitamin agar (humic acid 1.0 g, KCl 1.7 g, Na2HPO4 0.5 g, MgSO4·7H2O 0.5 g, CaCO3 0.02 g, FeSO4·7H2O, 0.01 g, B vitamins (0.5 mg each of thiamin, riboflavin, niacin, pyridoxin, calcium | [ | |
| Mangrove sediment | Starch casein agar (1% soluble starch, 0.03% casein, 0.2% KNO3, 0.2% NaCl, 0.005% MgSO4.7H2O, 0.2% K2HPO4, 0.02% CaCO3, 0.001% FeSO4.7H2O, 1.8% agar) | [ | |
| Mangrove soil | Starch casein agar [1% soluble starch, 0.03% casein, 0.2% KNO3, 0.2% NaCl, 0.005% MgSO4.7H2O, 0.2% K2HPO4, 0.02% CaCO3, 0.001% FeSO4.7H2O, 1.8% agar supplemented with cycloheximide (25 µg mL−1) and nystatin (10 µg mL−1)] | [ | |
| Rhizosphere soil of mangrove | NBRC medium 802 [1.0% (w/v) polypeptone, 0.2% (w/v) yeast extract, 0.1% (w/v) MgSO4.7H2O and 1.5% (w/v) agar] | [ | |
| Mangrove soil | ISP 2 medium [yeast extract 4.0 g, malt extract 10.0 g, dextrose 4.0 g, Distilled water 1 L and Bacto agar 20.0 g supplemented with cycloheximide (25 µg mL−1) and nystatin (10 µg mL−1)] | [ | |
| Mangrove soil | Starch casein agar [1% soluble starch, 0.03% casein, 0.2% KNO3, 0.2% NaCl, 0.005% MgSO4.7H2O, 0.2% K2HPO4, 0.02% CaCO3, 0.001% FeSO4.7H2O, 1.8% agar supplemented with cycloheximide (25 µg mL−1) and nystatin (10 µg mL−1)] | [ | |
| Mangrove sediment | Modified gause inorganic agar (20 g soluble starch, 1 g KNO3, 0.5 g K2HPO4, 0.5 g MgSO4.7H2O, 0.01 g FeSO4.7H2O, 15 g agar, 1 L aged seawater) | [ | |
| Mangrove soil | Starch casein agar [1% soluble starch, 0.03% casein, 0.2% KNO3, 0.2% NaCl, 0.005% MgSO4.7H2O, 0.2% K2HPO4, 0.02% CaCO3, 0.001% FeSO4.7H2O, 1.8% agar supplemented with cycloheximide (25 µg mL−1) and nystatin (10 µg mL−1)] | [ | |
| Rhizosphere soil of | Oatmeal agar [Oatmeal 20.0 g, agar 18.0 g, supplemented with novobiocin (25 µg mL−1), nystatin (30 µg mL−1), nalidixic acid (10 µg mL−1) and K2Cr2O7 (20 mg mL−1] | [ | |
| Mangrove soil | Marine agar 2216 (Difco) | [ | |
| Rhizosphere soil of mangrove | NBRC medium 802 [0.2% (w/v) polypeptone, 0.04% (w/v) yeast extract, 0.02% (w/v) MgSO4.7H2O and 1.5% (w/v) agar] supplemented with 5.0% (w/v) NaCl, 0.005% (w/v) cycloheximide and 0.002% (w/v) nalidixic acid | [ | |
| Mangrove sediment | Marine agar 2216 (Difco) | [ | |
| Mangrove sediment | Starch casein agar [1% soluble starch, 0.03% casein, 0.2% KNO3, 0.2% NaCl, 0.005% MgSO4.7H2O, 0.2% K2HPO4, 0.02% CaCO3, 0.001% FeSO4.7H2O, 1.8% agar supplemented with nalidixic acid (25 µg mL−1) and ketokonazole (100 µg mL−1)] | [ |
Number of new species of rare actinomycetes reported from marine environment between 2007 and 2017.
| Particular | 2007 to mid-2013 * | Mid-2013 to 2017 | Total (2007–2017) |
|---|---|---|---|
| New species reported | 80 | 97 | 177 |
| Novel families reported | 3 | - | 3 |
| Novel genera reported | 20 | 9 | 29 |
| Total families reported | 23 | 27 | 33 |
|
| |||
| Micromonosporaceae | 13 | 10 | 23 |
| Nocardioidaceae | 10 | 9 | 19 |
| Pseudonocardiaceae | 6 | 11 | 17 |
| Microbacteriaceae | 5 | 8 | 13 |
| Micrococcaceae | 5 | 8 | 13 |
| Demequinaceae | 1 | 11 | 12 |
| Nocardiopsaceae | 4 | 6 | 10 |
| Micrococcineae | 10 | - | 10 |
| Propionibacteriaceae | 4 | 4 | 8 |
| Intrasporangiaceae | 4 | 4 | 8 |
| Nocardiaceae | 2 | 4 | 6 |
| Streptosporangiaceae | 3 | 1 | 4 |
| Promicromonosporaceae | 3 | 1 | 4 |
| Cellulomonadaceae | 1 | 2 | 3 |
| Acidimicrobiaceae | 1 | 2 | 3 |
| Bogoriellaceae | 1 | 2 | 3 |
| Beutenbergiaceae | 1 | 1 | 2 |
| Thermomonosporaceae | 1 | 1 | 2 |
| Actinopolysporaceae | - | 2 | 2 |
| Brevibacteriaceae | - | 2 | 2 |
| Alteromonadaceae | 1 | - | 1 |
| Tsukamurellaceae | 1 | - | 1 |
| Iamiaceae | 1 | - | 1 |
| Euzebyaceae | 1 | - | 1 |
| Geodermatophilaceae | 1 | - | 1 |
| Actinomycetaceae | - | 1 | 1 |
| Rubrobacteraceae | - | 1 | 1 |
| Actinosynnemataceae | - | 1 | 1 |
| Gordoniaceae | - | 1 | 1 |
| Jiangellaceae | - | 1 | 1 |
| Kineosporiaceae | - | 1 | 1 |
| Dermacoccaceae | - | 1 | 1 |
| Dermabacteraceae | - | 1 | 1 |
* Adapted from Subramani and Aalbersberg [7].
Figure 1Total number of families, novel genera and new species of rare actinomycetes reported from different marine habitats between mid-2013 and 2017.
Antibiotics of therapeutic natural products derived from actinomycetes.
| Drug Name/Compound | Natural Product (NP) or Derivative | Source Organism | Chemical Class | Therapeutic Activity | Clinical Status (Year) | Reference |
|---|---|---|---|---|---|---|
|
| ||||||
| Telithromycin | Erythromycin (NP-derivative) |
| Macrolide | Antibacterial (G+ve/G−ve) | Approved (2001) | [ |
| Biapenem | Thienamycin (NP-derivative) |
| Carbapenem | Antibacterial (G+ve/G−ve) | Approved (2002) | [ |
| Ertapenem | Thienamycin (NP-derivative) |
| Carbapenem | Antibacterial (G+ve/G−ve) | Approved (2002) | [ |
| Daptomycin | Natural product |
| Lipopeptide | Antibacterial (G+ve) | Approved (2003) | [ |
| Doripenem | Thienamycin (NP-derivative) | Carbapenem | Antibacterial (G+ve/G−ve) | Approved (2005) | [ | |
| Tigecycline | Tetracycline (NP-derivative) |
| Tetracycline | Antibacterial (G+ve/G−ve) | Approved (2005) | [ |
| Tebipenem pivoxil | Thienamycin (NP-derivative) | Carbapenem | Antibacterial (G+ve/G−ve) | Approved (2009) | [ | |
| Telavancin | Vancomycin (NP-derivative) |
| Glycopeptide | Antibacterial (G+ve) | Approved (2009) | [ |
| Fidaxomicin | Natural product |
| Tiacumicin | Antibacterial (G+ve) | Approved (2011) | [ |
| Dalbavancin | Teicoplanin (NP-derivative) | Glycopeptide | Antibacterial (G+ve) | Approved (2014) | [ | |
| Oritavancin | Chloroeremomycin (NP-derivative) |
| Glycopeptide | Antibacterial (G+ve) | Approved (2014) | [ |
| Tazobactam | NP-derivative | Actinomycete strain | Penicillanic acid sulfone derivative and β-lactamase inhibitor | Antibacterial (G−ve) | Approved (2014) | [ |
|
| ||||||
| Salinosporamide A (Marizomib) | Natural product |
| Beta-lactone-gamma lactam | Multiple cancer | Phase I | [ |
| Arenamides A and B | Natural product | Peptide | Inflammation | Pre-clinical | [ | |
| Anthracimycin | Natural product | Polyketide | Anthrax | Pre-clinical | [ | |
G+ve: Gram positive; G−ve: Gram negative.
Numbers of new natural products/bioactive compounds produced by rare actinomycete genera from the marine environment between 2007 and 2017.
| Particular | 2007 to mid-2013 * | Mid-2013 to 2017 | Total (2007–2017) |
|---|---|---|---|
| Novel/new compounds reported | 100 | 167 | 267 |
| Total number of rare actinomycetes | 38 | 58 | 96 |
| Total genera reported | 15 | 24 | 28 |
|
| |||
|
| 12 | 40 | 52 |
|
| 9 | 37 | 46 |
|
| 20 | 21 | 41 |
|
| 3 | 14 | 17 |
|
| 18 | 2 | 20 |
|
| 1 | 3 | 4 |
|
| 1 | 1 | 2 |
|
| 1 | - | 1 |
|
| 11 | 5 | 16 |
|
| 3 | 5 | 8 |
|
| 7 | 3 | 10 |
|
| 1 | - | 1 |
|
| 2 | - | 2 |
|
| 1 | 5 | 6 |
|
| 10 | - | 10 |
|
| - | 2 | 2 |
|
| - | 2 | 2 |
|
| - | 1 | 1 |
|
| - | 3 | 3 |
|
| - | 2 | 2 |
|
| - | 4 | 4 |
|
| - | 3 | 3 |
|
| - | 1 | 1 |
|
| - | 4 | 4 |
|
| - | 1 | 1 |
|
| - | 4 | 4 |
|
| - | 3 | 3 |
|
| - | 1 | 1 |
* Adapted from Subramani and Aalbersberg [7].
Figure 2New pyrones produced by marine rare Nocardiopsis spp., Streptomonospora sp. and Saccharomonospora sp. between mid-2013 and 2017.
Figure 3Some novel natural products from marine Micromonospora spp. reported from mid-2013 to 2017.
Figure 4Some of the unique chemical moieties in natural products produced by marine rare actinomycetes between mid-2013 and 2017.
Figure 5Some unusual biologically active compounds produced by marine rare actinomycetes between mid-2013 and 2017.
Novel/new bioactive compounds produced by marine rare actinomycetes between mid 2013 and 2017.
| Compounds | Chemical Family/Class | Marine Source | Biological Activity | Reference |
|---|---|---|---|---|
| Halomadurones A–D | Halogenated electrophilic pyrones | Potent Nrf2-ARE activation | [ | |
| Levantilide C | 20-membered macrolide | Antiproliferative activity | [ | |
| Nocapyrones H–J | α-pyrones | Pro-inflammatory factor, stronger inhibitory effect on nitric oxide | [ | |
| Nocardiopsins C and D | Prolinyl-macrolactam polyketides | Not specified | [ | |
| Nocardiopyrone A | α-pyrone polyketide | Not specified | [ | |
| Nocardiamide A and B | Cyclic hexapeptides | Antimicrobial activity | [ | |
| Cyanosporasides C–F | Polyketides |
| Not specified | [ |
| Micromonolactam | Polyene macrocyclic lactam | No antimicrobial activity | [ | |
| Cyanogramide | Spirocyclic alkaloid |
| Multidrug-resistance (MDR) reversing activity | [ |
| Actinosporins A and B | Moderate activity against | [ | ||
| Solwaric acids A and B | Trialkyl-substituted aromatic acids | Antibacterial activity against MDR pathogens | [ | |
| Seriniquinone | Quinones | A selective anticancer agent | [ | |
| Cyanogrisides E–H | Acyclic bipyridine glycosides |
| Cytotoxicity | [ |
| Forazoline A | Polyketides | Anti-candida activity | [ | |
| Amycofuran | Benzofuran glycoside | Modest cytotoxicity | [ | |
| Amycolactam | Indole alkaloids | Cytotoxicity | [ | |
| Amycocyclopiazonic acid | Cyclopiazonic acid | Modest cytotoxicity | [ | |
| Dermacozines H–J | Heteroaromatic phenazines |
| Radical scavenging activity | [ |
| Microluside A | Antibacterial activity | [ | ||
| Nocapyrone R | α-pyrones | No cytotoxicity | [ | |
| Butremycin | Polycyclic tetramic acid macrolactams | Weak antibacterial activity | [ | |
| 5′-Methylthioinosine | Protonated aromatic tautomer | No antibacterial activity | [ | |
| Butrepyrazinone | Pyrazinone | No antibacterial activity | [ | |
| MBJ-0003 | Hydroxamate | Moderate cytotoxicity | [ | |
| Microbacterins A and B | Peptaibols |
| Potent cytotoxic activity | [ |
| Salinipostins A–K | Bicyclic Phosphotriesters | Antimalarial activity | [ | |
| Nocarimidazoles A and B | 4-aminoimidazole alkaloids | Weak antibacterial activity | [ | |
| Dimeric indole derivatives 1 and 2 | Dimeric indoles |
| Acetylcholinesterase (AchE) inhibitory activity | [ |
| Saccharothrixones A–D | Aromatic polyketides | Cytotoxic activity | [ | |
| Thiasporines A–C | Thiazine and Thiazole Derivatives |
| Cytotoxicity | [ |
| Diketopiperazine 1 | Diketopiperazine | Sterol | [ | |
| Isopimara-2-one-3-ol-8,15-diene | Pimarane Diterpene | Weak cytotoxicity | [ | |
| Lagumycin B, Dehydrorabelomycin, Phenanthroviridone, WS-5995 A | Angucyclines | Cytotoxicity | [ | |
| Micromonohalimane A and B | Halimane-type diterpenoids | Modest antibacterial activity against MRSA, bacteriostatic | [ | |
| Quinoline alkaloid | Alkaloid | Antibacterial activity | [ | |
| 1,4-dioxane derivative | Dioxane | Antibacterial activity | [ | |
| Pseudonocardides A–G | γ-butyrolactones | Antibacterial and cytotoxic activities | [ | |
| Curvularin macrolides 1–5 | Macrolides | Antibacterial and cytotoxic activities | [ | |
| α-pyrones 1–8 | α-pyrones | Moderate antibacterial activity | [ | |
| Compounds 1–12 | Benzamides, Indoles | Antibacterial, antifungal and cytotoxic activities | [ | |
| 3-benzyl-3α,4β-dihydroxypentan-2-one | Phenolics | Not specified | [ | |
| Marinopyrones A–D | α-pyrones | Inhibition of NO production | [ | |
| Glycerol 1-hydroxy-2,5-dimethyl benzoate | Salicylic derivative | Anti-MRSA activity | [ | |
| Isomethoxyneihumicin | Lactam-lactim tautomers |
| Strong cytotoxicity | [ |
| Microindolinone A | Novel indole | No anti-allergic and anti-proliferative activities | [ | |
| Nesterenkoniane | Novel cyclic ether |
| Moderate anti-allergic activity | [ |
| Nocapyrones O–S | α-pyrones | Cytotoxicity | [ | |
| Paulomycin G | Glycosylated paulomycins |
| Strong cytotoxic activity | [ |
| Saccharomonopyrones A–C | α-pyrones | Weak antioxidant activity | [ | |
| Tetrocarcin Q | Spirotetronate glycoside |
| Moderate antibacterial activity | [ |
| 22-dehydroxymethyl-kijanolide | Spirotetronate aglycone |
| No antibacterial activity | [ |
| 8-hydroxy-22-dehydroxymethyl-kijanolide | Spirotetronate aglycone |
| No antibacterial activity | [ |
| Microsporanates A–F | Spirotetronate glycosides |
| Antibacterial activity | [ |
| Tetrocarcin P | Spirotetronate glycoside |
| Antibacterial activity | [ |
| Nocazines F and G | Diketopiperazine | Excellent cytotoxicity | [ | |
| Kribellosides A-D | Alkyl glyceryl ethers | Antifungal and RNA 5’-triphosphatase inhibitor | [ | |
| Branimycins B and C | Macrolide |
| Antibacterial activities | [ |
| 1,2-naphthoquinone | Naphthalene derivative | No cytotoxicity | [ |
New bioactive compounds discovered from marine rare actinomycetes using genome-based approaches between mid-2013 and 2017.
| Compounds | Chemical Class/Family | Marine Source | Biological Activity | Reference |
|---|---|---|---|---|
| Taromycin A | Dichlorinated lipopeptide | Moderate bioactivity against MDR pathogens | [ | |
| Retimycin A | Quinomycin-like depsipeptide | Cytotoxicity against HCT-116 | [ | |
| Sioxanthin | Carotenoid | Siderophore | [ | |
| Lobosamides A–C | Polyene macrolactams | Anti-protozoan parasite, | [ | |
| Hexaricins A–C | Pentangular polyphenols | Not specified | [ | |
| Tetrocarcin N and O | Glycosidic spirotetronates | Modest antibacterial activity | [ | |
| Rifsaliniketal | Saliniketal | Not specified | [ | |
| Nenestatin A | Benzofluorene |
| Antibacterial activity | [ |